BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, has entered a collaboration with Merck to apply the company’s technology to design candidates for up to three drug discovery programs.   BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of o...